Analysis of amniotic fluid, maternal plasma, and cord blood for a human breast gross cystic disease fluid protein.

Amniotic fluid was analyzed for the presence of the 15,000 monomer molecular size glycoprotein found in human breast gross cystic disease fluid (GCDFP-15). From 24 weeks' gestation a log-linear increase in levels of GCDFP-15 was noted. The levels of GCDFP-15 doubled every 16 to 28 days, and the highest value recorded was 7,200 ng/ml.

The value of serial plasma levels of carcinoembryonic antigen and gross cyst disease fluid protein in patients with breast carcinoma and osseous metastases.

Serial plasma levels of the glucoprotein tumor markers carcinoembryonic antigen (CEA) and gross cyst disease fluid protein (GCDFP) were evaluated in 83 patients undergoing treatment for predominant osseous metastases from breast carcinoma. Abnormal plasma levels of CEA (greater than 10 ng/ml) and/or GCDFP (greater than 150 ng/ml) were observed in 53 (63.8%) subjects.

Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma.

A comparative evaluation of carcinoembryonic antigen (CEA) and gross cystic disease fluid protein (GCDFP) as plasma markers for human breast carcinoma has been performed. Both assays appear to be useful in patients with metastatic breast carcinoma. Of 216 patients under treatment for metastatic disease, 111 (51%) had abnormal plasma levels of CEA and/or GCDFP.